PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapyUS biotech Vedanta Biosciences has been awarded up to $76.9 million to develop VE303 for high-risk Clostridioides difficile (C. Share XPureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapyhttps://pharmaphorum.com/news/puretechs-vedanta-biosciences-gets-federal-funding-for-c-diff-microbiome-therapy/
PureTech’s Vedanta raises $27m for microbiome researchUS-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several Share XPureTech’s Vedanta raises $27m for microbiome researchhttps://pharmaphorum.com/news/puretechs-vedanta-raises-27m-for-microbiome-research/
